Immune Checkpoint Inhibition for Locally Advanced NSCLC: Time to Ask New Questions?
J Thorac Oncol
.
2022 Dec;17(12):1330-1332.
doi: 10.1016/j.jtho.2022.08.019.
Author
Jeffrey A Bogart
1
Affiliation
1
Department of Radiation Oncology, State University of New York Upstate Medical University, Syracuse, New York. Electronic address: BogartJ@upstate.edu.
PMID:
36410966
DOI:
10.1016/j.jtho.2022.08.019
No abstract available
Publication types
Editorial
Comment
MeSH terms
B7-H1 Antigen / therapeutic use
Carcinoma, Non-Small-Cell Lung* / drug therapy
Humans
Immune Checkpoint Inhibitors
Lung Neoplasms* / drug therapy
Substances
Immune Checkpoint Inhibitors
B7-H1 Antigen